1. Home
  2. TORO vs ALXO Comparison

TORO vs ALXO Comparison

Compare TORO & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Toro Corp.

TORO

Toro Corp.

N/A

Current Price

$6.06

Market Cap

174.5M

ML Signal

N/A

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

N/A

Current Price

$1.71

Market Cap

205.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TORO
ALXO
Founded
2022
2015
Country
Cyprus
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
174.5M
205.9M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
TORO
ALXO
Price
$6.06
$1.71
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$3.50
AVG Volume (30 Days)
25.0K
731.7K
Earning Date
04-15-2026
05-08-2026
Dividend Yield
36.86%
N/A
EPS Growth
N/A
26.36
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.95
$1.05
52 Week High
$8.50
$2.66

Technical Indicators

Market Signals
Indicator
TORO
ALXO
Relative Strength Index (RSI) 47.95 35.29
Support Level $4.87 $1.56
Resistance Level $6.15 $2.17
Average True Range (ATR) 0.27 0.09
MACD -0.08 -0.03
Stochastic Oscillator 20.03 7.14

Price Performance

Historical Comparison
TORO
ALXO

About TORO Toro Corp.

Toro Corp is engaged in the acquisition, ownership, chartering, and operation of oceangoing tanker and LPG carrier vessels, providing seaborne transportation services for crude oil, refined petroleum products, and liquefied petroleum gas. The company operates through three segments: the Eco tanker segment, the Non-Eco tanker segment, and the LPG carrier segment. It generates the majority of its revenue from the LPG carrier segment.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: